sign in sign up
<<
Home , Apremilast, Celgene, Pomalidomide

Fact Sheet

NEWS EVENTS MARCH 2008 PROFILE CELGENE ACQUIRES PHARMION Celgene Corporation, as a leader in global , has built an integrated discovery, In March 2008, Celgene Corporation completed its acquisition of Pharmion Corporation. development and commercialization platform This combination of two outstanding organizations came about as the result of the hard for drug and cell-based therapies that enables the work and talent of each and every employee. Celgene plans to build on both organization’s company to continue to develop value within accomplishments to reach the goal of becoming a leading global biopharmaceutical company its therapeutic franchise areas of cancer and while improving the lives of patients with unmet medical needs. inflammatory diseases. This target-to-therapeutic platform integrates both small molecule and This acquisition brings together three disease-altering therapies in REVLIMID®, THALOMID® cell-based and spans the critical functions and VIDAZA® and provides opportunities to build a new kind of organization focused on required to generate a large and diverse pipeline critical areas of medicine, turning incurable cancers into chronic manageable diseases and of innovative next generation drugs and cell helping healthcare providers deliver positive outcomes for their patients. therapies that address the source of the disease and not just the symptoms. DRIVING GLOBAL EXPANSION FRONT PAGE – we need to add the Euro- BUILDING ON SUCCESS REVLIMID receives Orphan Drug Status in Japan for multiple indications pean Approval for REVLIMID under Driving WITH THE PHARMION February Global Expansion- ACQUISITION 2008 VIDAZA accepted for review by EMEA for high-risk MDS Date in box June 2007 REVLIMID granted full Advances Celgene’s goal to become the leader in blood cancers PHARMION Receives Positive Opinion for Treatment marketing authorization by the European Commission for of First-line from European Medicines Agency use in combination with as a treatment for Leverages Celgene’s clinical, regulatory patients with multiple myeloma who have received at least and commercial potential worldwide January REVLIMID receives marketing authorization approval from Australian one prior therapy Creates substantial opportunity to 2008 Therapeutic Good Administration for treatment of Multiple Myeloma maximize VIDAZA’s potential through REVLIMID receives marketing authorization approval from Canadian combination studies as a result of two BACK PAGE – Therapeutic Products Directorate for treatment of deletion 5q MDS great companies coming together 1. Under Brian Gill’s title take out the Accelerates long-term operational and word “Global” More than 113 abstracts presented at ASH 2007; 25 oral presentations financial opportunities December including updated clinical data for REVLIMID in newly diagnosed multiple 2. Under Investment Considerations Broadens portfolio of disease- 2007 myeloma, non-deletion 5q MDS, chronic lymphocyctic leukemia (CLL) and section – change $2.7 billion to $2.5 billion altering therapies non-hodgkin’s lymphoma (NHL) 3. Under second bullet under Invest- Complements and expands Celgene’s industry leading programs for safety, September ment Considerations needs to read like REVLIMID, in combination with dexamethasone, was compendia listed for access and patient support 2007 newly diagnosed multiple myeloma this: Lead clinical candidates REVLIMID and REVENUE, R&D, & EPS Pharmion released landmark survival data on VIDAZA from a Phase III VIDAZA offer near-term life transforming 1400 August controlled trial in higher risk MDS patients, VIDAZA showed a survival 1300 2007 potential to turn incurable cancers into benefit of 9.4 months compared to conventional care 1200

chronic diseases 1100 REVLIMID granted full marketing authorization by the European

1000 June Commission for use in combination with dexamethasone as a 2007 treatment for patients with multiple myeloma who have received at PIPELINE – 900 least one prior therapy 800 Total Revenue R&D Investment 700 EPS 600

500

400 ORAL ANTI-INFLAMMATORY FRANCHISE

300 $Millions On May 22, Celgene announced plans to advance the development of leading oral 200 anti-inflammatory candidates across a broad range of inflammatory diseases. CC-10004 $1.00 100 (), an oral TNF antagonist and anti-inflammatory agent has demonstrated significant 0 0 EPS -0.12 -0.02 -0.08 0.08 0.15 0.18 0.53 1.06 activity and an excellent side effect profile in a placebo controlled proof-of-mechanism trial in -$1.00 -100 . Based on these results, Celgene is accelerating clinical and regulatory strategies for ’00 ’01 ’02 ’03 ’04 ’05 ’06 ’07 CC-10004 in psoriasis, , rheumatoid arthritis and other inflammatory diseases. CELGENE CORPORATION 86 Morris Avenue • Summit, NJ 07901 • P: 908-673-9000 • F: 908-673-9001 • www.celgene.com

PRODUCT PIPELINE Regulatory Filing IMiDs® Compounds: Pre-clinical Phase I Phase II Phase III and Approval / INVESTOR CONTACT *FDA Registered REVLIMID®: Multiple Myeloma (US) ...... INFORMATION REVLIMID: MDS deletion 5Q (US) ...... Brian Gill REVLIMID: Multiple Myeloma (EMEA)...... Vice President REVLIMID: MDS deletion 5Q (EMEA)...... Corporate Communications REVLIMID: Multiple Myeloma (SWISS) . . . . . Email: [email protected] REVLIMID: MDS deletion 5Q (SWISS) . . . . . Mary Ann Ondish REVLIMID: MDS ...... Assoc. Director REVLIMID: CLL...... Investor Relations REVLIMID: NHL ...... Email: [email protected] REVLIMID: Solid Tumors ...... CELGENE EXECUTIVE (CC-4047): Myelofibrosis. . . . . OFFICERS pomalidomide (CC-4047): Multiple Myeloma . . Sol J. Barer, Ph.D. pomalidomide (CC-4047): Solid Tumors . . . . Chief Executive Officer pomalidomide (CC-4047): Sickle Cell Anemia CC-11006: MDS ...... Robert J. Hugin President and COO CC-10015: Rheumatology...... CC-16057: Oncology/Inflammation ...... David W. Gryska, Senior Vice President and CFO THALOMID®: Multiple Myeloma (US) ...... ANALYST COVERAGE ENL...... Alliance Bernstein Banc of America Thalidomide Pharmion 50 MG: Bear Stearns BMO Capital Markets Multiple Myeloma (EMEA)...... Citigroup Smith Barney Other Cancer...... Cowen Credit Suisse Securities VIDAZA® (azacitidine): Friedman, Billings, Ramsey MDS (US) ...... Goldman Sachs Jeffries MDS (EMEA) ...... JMP Securities AML ...... JP Morgan Chase Lazard Capital Markets Solid Tumors ...... Leerink Swan MDS/AML (Oral azacitidine) . . . . Lehman Brothers ® Merrill Lynch ALKERAN : Morgan Stanley Multiple Myeloma\Ovarian Cancer Robert W. Baird Rodman & Renshaw Ritalin®/FOCALIN™: Thomas Weisel Partners FOCALIN: ADHD ...... UBS Wachovia Ritalin LA®: ADHD ...... William Blair & Co FOCALIN XR™: ADHD ...... INVESTMENT Anti-Inflammatory: CONSIDERATIONS apremilast (CC-10004): Psoriasis ...... apremilast (CC-10004): Psoriatic Arthritis . . . Profitable and accelerating revenue apremilast (CC-10004): Behcet’s Syndrome . . . growth supporting development of CC-11050: Inflammatory ...... multiple clinical compounds across several high potential programs Kinase Inhibitors: JNK 930: Fibrotic Diseases ...... Lead clinical candidates REVLIMID and VIDAZA offer near-term life Ligase Inhibitors: transforming potential to turn incurable Ubiquitin Ligase: Cancer ...... cancers into chronic diseases Stem Cells and Tissue Products: Cutting edge research in cellular Lifebank USA: Private Stem Cell Banking . . . . . signaling technology delivering next HPP: Transplants ...... generation therapies with potential to PDA-001: Autoimmune/Cancer...... change standard of care BIOVANCE and Acelagraft™ ...... Strong, evolving intellectual property MGCD0103: estate supporting a broad, deep, Solid Tumors (w/ gemcitabine) . . . proprietary pipeline addressing large, Hematologic Malignancies...... international commercial opportunities w/ Vidaza in MDS/AML ...... Financial strength with over $2.5 w/ Vidaza in lymphoma ...... billion in cash and marketable AMRUBICIN®: securities positioned to support SCLC...... long-term growth strategy w/ Cisplatin for SCLC ...... Effective senior management team Breast Cancer...... experienced in successful execution of ACTIVIN INHIBITOR corporate strategies ACE-011 Cancer-related bone loss ......

The products represented as in development and found in the product pipeline are intended for investors and members of the media to provide general information on Celgene. This information is not represented to be a complete description and is subject to change without notice. Celgene Corporation may from time to time update this information but does not warrant that will take place at any particular time nor assume any obligation to update this information.